Biopharmaceutical companies like Dynavax are on the cutting edge of cancer prevention, adding to their risk as well as their intrigue for investors. A Stanford University study recently published in the journal Science Immunology found that adding DVAX's vaccine to Dragonfly Therapeutics' interleukin-12 drug and injecting it into cancer tumors can mobilize B cells, inducing a systemic antitumor response that helps prevent relapse. With a $1.4 billion market capitalization, Dynavax has multiple partnerships to develop iterations of COVID-19 vaccines and has a hepatitis B vaccine candidate in the works. Plenty of heavy hitters, such as Novartis AG ( NVS ), are backing cancer vaccine research efforts, but Dynavax has so far managed to stay ahead of the curve. Still down more than 14% year to date as of June 9, DVAX has gained about 16% in the last three months and has a price-earnings ratio of 16. Morningstar assigns a fair value estimate of $20.50 to DVAX, which closed at $12.02 on June 9.